Investment Management Corp of Ontario Has $35.23 Million Position in IDEXX Laboratories, Inc. $IDXX

Investment Management Corp of Ontario raised its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 52,069 shares of the company’s stock after buying an additional 3,274 shares during the period. Investment Management Corp of Ontario’s holdings in IDEXX Laboratories were worth $35,226,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Gotham Asset Management LLC grew its position in shares of IDEXX Laboratories by 22.8% in the 4th quarter. Gotham Asset Management LLC now owns 59,738 shares of the company’s stock valued at $40,415,000 after buying an additional 11,095 shares during the last quarter. Evolve Private Wealth LLC bought a new stake in shares of IDEXX Laboratories in the 4th quarter valued at about $419,000. First Manhattan CO. LLC. grew its position in shares of IDEXX Laboratories by 139.9% in the 4th quarter. First Manhattan CO. LLC. now owns 2,171 shares of the company’s stock valued at $1,469,000 after buying an additional 1,266 shares during the last quarter. Capitolis Liquid Global Markets LLC bought a new stake in shares of IDEXX Laboratories in the 4th quarter valued at about $1,780,000. Finally, City National Bank of Florida MSD bought a new stake in shares of IDEXX Laboratories in the 4th quarter valued at about $203,000. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Down 4.7%

NASDAQ IDXX opened at $546.09 on Thursday. The business has a 50 day simple moving average of $562.51 and a 200 day simple moving average of $622.66. IDEXX Laboratories, Inc. has a one year low of $506.91 and a one year high of $769.98. The stock has a market capitalization of $43.08 billion, a P/E ratio of 40.21, a P/E/G ratio of 3.13 and a beta of 1.55. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter last year, the firm posted $2.91 earnings per share. The firm’s revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Research analysts expect that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

Wall Street Analyst Weigh In

IDXX has been the topic of a number of analyst reports. Stifel Nicolaus reduced their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Wall Street Zen raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, June 13th. Citigroup initiated coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price for the company. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Finally, UBS Group lowered their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Seven equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.